Denmark· DK-28106022517
Poteligeo
A mogamulizumab product containing mogamulizumab, registered in Denmark by Kyowa Kirin Holdings B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Mogamulizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX09 (mogamulizumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Mogamulizumab · ATC L01FX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mogamulizumab costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mogamulizumab · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$432.02
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Mogamulizumab
- Manufacturer
- Kyowa Kirin Holdings B.V.
- Country
- Denmark (DK)
- ATC code
- L01FX09
- ATC class
- Mogamulizumab
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106022517
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
74 interactions on record for mogamulizumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mogamulizumab · interactions on record
74 records
- 29 severe
- 38 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FX09
Mogamulizumab, as other registers publish it.
- FinlandPoteligeoKyowa Kirin Holdings B.V.
- FinlandPoteligeoOrifarm Oy
- PolandPoteligeoKyowa Kirin Holdings B.V.
- NorwayPoteligeoKyowa Kirin Holdings B.V.
- IcelandPoteligeoKyowa Kirin Holdings B.V.
- CanadaPOTELIGEOKYOWA KIRIN, INC.
- United StatesPOTELIGEOKyowa Kirin, Inc.
- CzechiaPOTELIGEOKyowa Kirin Holdings B.V., Hoofddorp
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9f1b5e6-148f-4834-86a9-bf040bf288ab GET /v1/drugs/a9f1b5e6-148f-4834-86a9-bf040bf288ab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "4 mg/ml",
"auth_role": "MOD",
"dk_drugid": "28106022517",
"substance": "Mogamulizumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "43426"
}See everything about mogamulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.